Press Release

Sysmex Begins Supplying Reagents for U.S. Based Laboratory Developed Test (LDT) Measuring Amyloid Beta (Aβ) in Blood

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) has begun supplying reagents to measure Aβ in the blood for Labcorp's Amyloid Beta (Aβ) LDT1. Labcorp is a global leader of innovative and comprehensive laboratory services. Utilizing samples from patients suspected of having Alzheimer's disease, this LDT assists in identifying Aβ accumulation in the brain— thought to be a leading cause of the disease.

Sysmex is actively pursuing global IVD clearances for the intended use of this reagent and continues to leverage diagnostic technologies in Japan and overseas to improve people’s lifetime healthcare journey and support healthy lives.


1 A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed, manufactured, and used within a single laboratory.
  • The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.

Back to "News"